The Lantus market is a subset of the larger biopharmaceutical industry, focusing on the development and commercialization of biosimilars and biosuperiors of the insulin glargine product, Lantus. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Both biosimilars and biosuperiors of Lantus are developed to provide a more affordable and effective alternative to the original product. The Lantus market is highly competitive, with many companies vying for a share of the market. Some of the major players in the market include Sanofi, Eli Lilly, Merck, Pfizer, Novo Nordisk, and Biocon. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
